SRR814563
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- DNA_REPAIR+0.171
- PI3K_AKT_MTOR_SIGNALING+0.147
- OXIDATIVE_PHOSPHORYLATION+0.136
- HEME_METABOLISM+0.130
- UNFOLDED_PROTEIN_RESPONSE+0.127
- MYOGENESIS+0.106
- CHOLESTEROL_HOMEOSTASIS+0.093
- MITOTIC_SPINDLE+0.071
- ANDROGEN_RESPONSE+0.060
- MYC_TARGETS_V1+0.058
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.516
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.432
- INTERFERON_GAMMA_RESPONSE-0.409
- ANGIOGENESIS-0.397
- COAGULATION-0.374
- PANCREAS_BETA_CELLS-0.353
- IL6_JAK_STAT3_SIGNALING-0.352
- KRAS_SIGNALING_UP-0.351
- ALLOGRAFT_REJECTION-0.340
- TGF_BETA_SIGNALING-0.333
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR655684 | GTEX | — | 0.938 |
| 2 | SRR657915 | GTEX | — | 0.932 |
| 3 | SRR1097752 | GTEX | — | 0.928 |
| 4 | SRR1362060 | GTEX | — | 0.914 |
| 5 | SRR1402473 | GTEX | — | 0.911 |
| 6 | SRR1409899 | GTEX | — | 0.909 |
| 7 | SRR1401953 | GTEX | — | 0.908 |
| 8 | SRR1477773 | GTEX | — | 0.904 |
| 9 | SRR1417981 | GTEX | — | 0.903 |
| 10 | SRR1401062 | GTEX | — | 0.899 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| DNA_REPAIR | 0.171 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.147 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.136 | Remibrutinib | — uncovered |
| HEME_METABOLISM | 0.130 | Temsirolimus | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.127 | Idelalisib | — uncovered |
| MYOGENESIS | 0.106 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.093 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.071 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.060 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.058 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.050 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.047 | Idelalisib | — uncovered |
| PEROXISOME | 0.039 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.033 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.028 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.024 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.010 | Inavolisib | — uncovered |